FIELD: immunology; biotechnology.
SUBSTANCE: disclosed is an antigen-binding molecule capable of binding a CD3 receptor complex containing variable light and heavy chain domains, characterized by amino acid sequences of complementarity determining regions (CDR). In addition, use of a bispecific antigen-binding molecule capable of binding CD3 and CD19, for creating a drug for treating malignant B-cell diseases or B cell depletion, particularly for treating hematological B-cell diseases, such as acute lymphoblastic leukemia and B-cell lymphomas, including their refractory or recurrent forms.
EFFECT: thanks to the ability to bind CD3 and activate T-cells, the antigen-binding molecule of the present invention can be used in designing various bispecific therapeutic antibodies.
12 cl, 11 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ASYMMETRIC HETERODIMERS COMPRISING ANTI-CD3 CONSTRUCTS | 2013 |
|
RU2650868C2 |
| TEST SYSTEM FOR ANALYSING FUNCTIONAL ACTIVITY OF ANTIBODIES AGAINST PD-1 AND ANTIBODIES AGAINST PD-L1 | 2019 |
|
RU2731896C1 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| CD19 X CD3-SPECIFIC POLYPEPTIDES AND THEIR APPLICATION | 1999 |
|
RU2228202C2 |
| BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| BISPECIFIC ANTIBODIES AGAINST CD3*CD19 | 2015 |
|
RU2651776C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
